Published: Apr 05, 2024 By Tristan Manalac
Pictured: Boehringer Ingelheim’s headquarters in Silicon Valley/iStock, Sundry Photography
Boehringer Ingelheim is laying off some of its sales staff due to the slow uptake of its Humira (adalimumab)…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
